

**CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY**

NAME

Susan Unipan Lattimore

DATE

2/01/2024

I. PRESENT POSITION AND ADDRESS

Academic Rank:

Assistant Professor

Department/Division:

Institute on Development and Disability/The Hemophilia Center

Professional Address:

707 SW Gaines St
Portland, OR 97239

E-Mail Address:

lattimor@ohsu.edu

II. EDUCATION

Undergraduate:

1994 BS Nursing
University of Pennsylvania
Philadelphia, PA

Graduate:

2018 GC Public Health
Oregon Health & Science University
Portland, OR

Licenses:

Oregon, July 1, 2010, Active, 201042518RN, 3/1/2024
Tennessee, 2005-2011, Inactive
Georgia, 2001-2006, Inactive
Pennsylvania, 1994-2001, Inactive

III. PROFESSIONAL EXPERIENCE

Academic:

2023-present Assistant Professor, Oregon Health & Science University
2016-2023 Instructor of Pediatrics, Oregon Health & Science University

Administrative:

2017-present Associate Director, The Hemophilia Center – Oregon Health & Science University

2019-present Regional Director, Mountain States Regional Hemophilia Network
2016-2019 Regional Coordinator, Mountain States Regional Hemophilia Network
2015-2017 Research Director, The Hemophilia Center – Oregon Health & Science University

Hospital/Clinical Appointments:

2013-2016 Senior Research Nurse, The Hemophilia Center, Oregon Health & Science University
Portland, Oregon
2010-2013 Senior Research Nurse, Pediatric Clinical Research Office, Oregon Health & Science
University, Portland, Oregon
2005-2010 Research Nurse Specialist III, Division of Trauma and Surgical Critical Care, Vanderbilt
University Medical Center. Nashville, Tennessee
2001-2005 Charge Nurse, Perioperative Services, Memorial Health University Medical Center,
Savannah, Georgia
2001-2004 Nurse Researcher, Section on Stroke Diagnostics and Therapeutics, National Institute of
Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
1999-2001 Program Coordinator / Nurse Researcher, Section on Stroke Diagnostics and
Therapeutics. National Institute of Neurological Disorders and Stroke, National Institutes
of Health. Bethesda, Maryland
1997-1999 Research Program Coordinator, Department of Neurosciences, University of
Pennsylvania Medical Center. Philadelphia, Pennsylvania
1996-1997 Charge Nurse, Neuroscience Acute Care Unit. University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
1994-1996 Staff Nurse, Neuroscience Acute Care Unit, University of Pennsylvania Medical Center,
Philadelphia, Pennsylvania

IV. SCHOLARSHIP

Area(s) of Research/Scholarly Interest:

1. Ameliorating health disparities through public health interventions in people with bleeding disorders
2. Surveillance and population health in people with bleeding disorders
3. Evaluation and impact of access to care interventions in rare disease

Grants and Contracts:

Federal

Current

Hemophilia Treatment Centers (SPRANS) Source: Health Resources and Service Administration (H30MC24049), Amount: \$2,500,000 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.26 Timeframe: 6/1/2022 – 5/31/2027

Community Counts: Public Health Surveillance for Bleeding Disorders Source: Centers for Disease Control and Prevention via American Thrombosis and Hemostasis Network (NU27DD000020-01-00), Amount: \$1,513,645 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.21 Timeframe: 9/30/2021 – 9/29/2025

Completed

Hemophilia Treatment Centers (SPRANS) Source: Health Resources and Service Administration (H30MC24049), Amount: \$2,500,000 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.26 Timeframe: 11/1/2019 – 5/31/2022

Hemophilia Treatment Centers (SPRANS) Source: Health Resources and Service Administration (H30MC24049), Amount: \$2,000,000 Role: Regional Coordinator; PI: Michael Recht. % Effort: Funded FTE 0.25 Timeframe: 6/1/2016 – 10/31/2019

Community Counts: Public Health Surveillance for Bleeding Disorders Source: Centers for Disease Control and Prevention via American Thrombosis and Hemostasis Network (1U27DD001155-01), Amount: \$302,729 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.21 Timeframe: 9/30/2019 – 9/29/2020

Other Support

Current

Title: ATHN 7: A natural history cohort study of the safety, effectiveness and practice of treatment for people with hemophilia. Source: American Thrombosis and Hemostasis Network, Amount: \$73,900 PI: Susan Lattimore. % Effort: Funded FTE 0.05 Timeframe: 1/1/2019 – 5/31/2024

Publications/Creative Work:

Peer-reviewed

1. Byams V, Baker JR, Bailey C, Connell NT, Creary MS, Curtis RG, Dinno A, Guelcher CJ, Kim M, Kulkarni R, **Lattimore S**, Norris KL, Ramirez L, Skinner MW, Symington S, Tobase P, Vazquez E, Warren BB, Wheat E, Buckner TW. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science. *Expert Rev Hematol.* 2023 Mar; 16 (sup1):87-106.
2. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, **Lattimore S**, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Gene therapy with Etranacogene dezaparvovec for hemophilia B. *N Engl J Med.* 2023 Feb 23;388(8):706-718.
3. Valentino LA, Baker JR, Butler R, Escobar M, Frick N, Karp S, Koulianos K, **Lattimore S**, Nugent D, Pugliese JN, Recht M, Reding MT, Rice M, Thibodeaux CB, Skinner M. Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders. *J Blood Med.* 2021 Oct; 12:897-911.
4. Croteau SE, Wheeler AP, Khan O, Haley KM, Borst AJ, **Lattimore S**, Yeung, CT, Iorio A. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. *Res Pract Thromb Haemost* 2020; 4(2):326-333.
5. Von Drygalski A, Giermasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Long A, Rug R, Sawyer EK, Pipe SW. Etranacogene dezaparvovec (AMT-061 phase 2b):

normal/near normal FIX activity and bleed cessation in hemophilia B. *Blood Adv* 2019; 3(21):3241-3247

6. Rocheleau AD, Khader A, Ngo ATP, Boehnlein C, McDavitt C, **Lattimore S**, Recht M, McCarty OJT, Haley KM. Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. *Pediatr Res* 2018; 83(3):693-701.
7. Haley KM, **Lattimore S**, McDavitt C, Khader A, Boehnlein C, Baker-Groberg S, Ngo A, McCarty OJT, Recht M. Identification of qualitative platelet disorders in adolescent women with heavy menstrual bleeding. *Blood*. 2016; 128(22): 49222-4926.
8. Baker-Groberg SM, **Lattimore S**, Recht M, McCarty OJT, Haley KM. Assessment of neonatal platelet adhesion, activation, and aggregation. *J Thromb Haemost* 2016; 14(4):815-27.
9. Kang DW, **Lattimore SU**, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. *Arch Neurol* 2006; 63(12):1730-3.
10. Merino JG, **Lattimore SU**, Warach S. Telephone assessment of stroke outcome is reliable. *Stroke* 2005; 36(2):232-3.
11. **Lattimore SU**, Chalela J, Davis L, DeGraba T, Ezzedine M, Haymore J, Nyquist P, Baird AE, Hallenbeck J, Warach S. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: The NINDS Suburban Hospital stroke center experience. *Stroke* 2003; 34(6):e55-7.
12. Warach S, **Unipan S**, Olan WJ. Routine screening for IV tPA therapy less than 3 hours with MRI: initial clinical experience. *Stroke* 2000; 32:371.
13. Conroy MB, **Unipan S**, Kimmel SE, Kasner SE. Helicopter transfer offers a potential benefit to patients with acute stroke. *Stroke* 1999;30(12):2580-4

Peer-Reviewed Electronic Publications

1. Roberts JC, **Lattimore S**, Recht M, Jackson S, Gue D, Squire S, Robinson KS, Price V, Denne M, Richardson S, Rockwood K. Goal attainment scaling for haemophilia (GAS-Hem): testing the feasibility of a new patient-centric outcome measure in people with haemophilia. *Haemophilia* 2018; 24(4):e199-e206

Peer-Reviewed Abstracts

1. Pipe S, Leebeek F, Recht M, Key N, **Lattimore S**, Castaman G, Coppens M, Li Y, Monahan P, Miesbach W. Phase 3 HOPE-B trial of etranacogene dezaparvovec in severe/moderately severe hemophilia b. Oral presentation. International Society on Thrombosis and Hemostasis Congress. Montreal, Quebec. June 2023.
2. Pipe S, Leebeek F, Recht M, Key N, **Lattimore S**, Castaman G, Cooper D, Verweij S, Dolmetsch R, Tarrant J, Li Y, Monahan P, Miesbach W. Durability of bleeding protection and factor IX activity levels are demonstrated in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (titers $\leq 1:678$) with comparable safety in the phase 3 HOPE-B clinical trial of etranacogene dezaparvovec gene therapy for haemophilia B. German Society for Thrombosis and Haemostasis Research Congress. Oral presentation. February 2023.

3. Sirianna V, **Lattimore S**, Shearer R, Shabtaie K, Ashton M, Riske B, Baker J. COVID-19 impact on patient satisfaction with US hemophilia treatment centers. Poster. ATHN Data Summit. Virtual. October 2022.
4. **Lattimore S**, Sirianna V, Shearer R, Ashton M, Shabtaie K, Riske B, Baker J. Patient satisfaction with US hemophilia treatment centers in 2020: examining video visits and COVID-19. Poster. National Hemophilia Foundation Bleeding Disorders Conference. Houston, TX. August 2022.
5. Durben N, Higashi H, **Lattimore S**, Smith K. Mindfulness based yoga for people with bleeding disorders and chronic pain. Poster and Plenary Session. National Hemophilia Foundation Bleeding Disorders Conference. Houston, TX. August 2022.
6. Sirianna V, **Lattimore S**, Shearer R, Shabtaie K, Riske B, Ashton M, Baker J. Telehealth and COVID-19 impact on patient satisfaction with US hemophilia treatment centers. Poster and lightning round presentation. World Hemophilia Federation Congress. Montreal, Quebec. May 2022.
7. Mlesbach W, Leebeek FW, Recht M, Key NS, **Lattimore S**, Castaman G, Coppens M, Cooper D, Slawka S, Verweij S, Gut R, Dolmetsch R, Li Y, Monahan PE, Pipe SW, HOPE-B Investigators. Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: Stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B. Oral presentation. European Association for Haemophilia and Allied Disorders Annual Congress. Virtual. February 2022.
8. Mlesbach W, Leebeek FW, Recht M, Key NS, **Lattimore S**, Castaman G, Coppens M, Cooper D, Slawka S, Verweij S, Gut R, Dolmetsch R, Li Y, Monahan PE, Pipe SW, HOPE-B Investigators. Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: Stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B. Poster. European Association for Haemophilia and Allied Disorders Annual Congress. Virtual. February 2022.
9. **Lattimore S**, Lane H, Phillips A, Blue A. Region-wide quality improvement in patient engagement: Return visits at HTTCs in the Mountain States Hemophilia Network. Poster. American Thrombosis and Hemostasis Network Data Summit. Virtual. October 2021.
10. Baker JR, **Lattimore S**, Shearer R, Sirianna V, Shabtaie K, Ashton M, Riske B. COVID-19 impact on patient satisfaction with US hemophilia treatment centers. Poster. American Thrombosis and Hemostasis Network Data Summit. Virtual. October 2021.
11. Journeycake J, Caicedo J, Cheng D, Denne M, Guelcher C, **Lattimore S**, Mokdad A, Ragni M, Recht M, Sidonio RF, Takemoto C, Tarantino MD, Watson C, Neufeld EJ. Dosing, patient satisfaction and other patient-reported outcomes after switching to rurioctocog alfa pegol in ATHN 2: A longitudinal, observational study of previously treated hemophilia patients switching coagulation replacement factor products. Poster. American Thrombosis and Hemostasis Network Data Summit. Virtual. October 2021.
12. Journeycake J, Caicedo J, Cheng D, Denne M, Guelcher C, **Lattimore S**, Mokdad A, Ragni M, Recht M, Sidonio RF, Takemoto C, Tarantino MD, Watson C, Neufeld EJ. Factor utilization in patients with hemophilia A after switching to rurioctocogalfa pegol in the ATHN 2 study. Oral presentation. American Thrombosis and Hemostasis Network Data Summit. October 2021. Virtual.

13. Journeycake J, Caicedo J, Cheng D, Denne M, Guelcher C, **Lattimore S**, Mokdad A, Ragni M, Recht M, Sidonio RF, Takemoto C, Tarantino MD, Watson C, Neufeld EJ. Clinical outcomes in patients with hemophilia A after switching to rurioctocog alfa pegol prophylaxis in the ATHN 2 study. Poster. American Thrombosis and Hemostasis Network Data Summit. Virtual. October 2021.
14. Baker J, **Lattimore S**, Shearer R, Ashton M, Shabtaie K, Sirianna V, Riske B. COVID-19 impact on satisfaction with US hemophilia treatment centers. Poster. National Hemophilia Foundation Bleeding Disorders Conference. Virtual. August 2021.
15. Pipe SW, Leebeek FW, Recht M, Key NS, **Lattimore S**, Castaman G, Sawyer EK, Verweij S, Colletta V, Cooper D, Dolmetsch R, Miesbach W. 52-week efficacy and safety of Etranacogene dezaparovec in adults with severe or moderate-severe hemophilia B: data from the phase 3 HOPE-B gene therapy trial. Poster. International Society on Thrombosis and Haemostasis Congress. Virtual. July 2021.
16. Leebeek FW, Miesbach W, Recht R, Key NS, **Lattimore S**, Castaman G, Sawyer EK, Cooper D, Ferreira V, Pipe SW. Clinical outcomes in adults with hemophilia B with and without pre-existing neutralizing antibodies to AAV5: 6-month data from the phase 3 etranacogene dezaparovec HOPE-B gene therapy trial. Oral presentation. International Society on Thrombosis and Haemostasis Congress. Virtual. July 2021.
17. Journeycake J, Caicedo J, Cheng D, Denne M, Guelcher C, **Lattimore S**, Mokdad A, Ragni M, Recht M, Sidonio RF, Takemoto C, Tarantino MD, Watson C, Neufeld EJ. Clinical outcomes in patients with haemophilia after switching to rurioctocog alfa pegol prophylaxis in the ATHN 2 study. Oral presentation. European Association for Haemophilia and Allied Disorders Congress. Virtual. February 2021.
18. Journeycake J, Caicedo J, Cheng D, Denne M, Guelcher C, **Lattimore S**, Mokdad A, Ragni M, Recht M, Sidonio RF, Takemoto C, Tarantino MD, Watson C, Neufeld EJ. Factor utilization in patients with haemophilia A after switching to rurioctocog alfa pegol I the ATHN 2 study. Poster presentation. European Association for Haemophilia and Allied Disorders Congress. Virtual. February 2021.
19. Pipe SW, Recht M, Key NS, Leebeek FW, Castaman G, **Lattimore SU**, van der Valk P, Peerlinck K, Coppens M, O'Connell N, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons RS, Visweshwar N, Crary S, Kazmi R, Symington E, Escobar MA, Gomez M, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Bajwa N, Gut R, Miesbach W. Efficacy and safety of Etranacogene dezaparovec in adults with severe or moderate-severe hemophilia B: first data from the phase 3 HOPE-B gene therapy trial. Oral presentation. European Association for Haemophilia and Allied Disorders Congress. Virtual. February 2021.
20. Von Drygalski A, Giermasz A, Cataman G, Key NS, **Lattimore SU**, Leebeek FW, Miesbach WA, Recht M, Gomez E, Gut R, Pipe SW. Etranacogene dezaparoved (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B: Two-year data from a Phase 2b trial. Oral presentation. American Society of Hematology Annual Meeting. Virtual. December 2020.
21. Journeycake JM, Recht M, Guelcher C, Neufeld EJ, Ragni MV, Sidonio RF, Takemoto C, Tarantino MD, Cheng D, **Lattimore SU**, Caicedo J, Denne M. Dosing, patient satisfaction and other patient-reported

- outcomes after switching to rurioctocog alfa pegol in Athn 2: a longitudinal, observational study of previously treated hemophilia patients switching coagulation replacement factor products. Poster. American Society of Hematology Annual Meeting. Virtual. December 2020.
22. Pipe SW, Recht M, Key NS, Leebeek FW, Castaman G, **Lattimore SU**, van der Valk P, Peerlinck K, Coppens V, O'Connell N, Pasi J, Kapmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons RS, Visweshwar N, Crary S, Kazmi R, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Baima N, Gut R, Miesbach WA. First data from the Phase 3 HOPE-B gene therapy trial: efficacy and safety of Etranacogene dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in adults with severe or moderate-severe hemophilia B treated irrespective of pre-existing anti-capcid neutralizing antibodies. Late-breaking oral presentation. American Society of Hematology Annual Meeting. Virtual. December 2020.
 23. **Lattimore SU**, Cox A, Haley KM, Hofstetter MT, Smith K. Does distance to hemophilia treatment center impact use of hemophilia treatment services? Poster. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020.
 24. Hofstetter M, Smith K, **Lattimore SU**. Engaging patients and families at emicizumab initiation. Poster. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020.
 25. Wagner D, **Lattimore SU**, Harris M, Haley K, Recht M, Stang E, Spiro K. Socially Vulnerable Youth with Bleeding Disorders: Piloting Novel Interventions in Children's Healthcare (NICH). Oral presentation. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020.
 26. Baker J, **Lattimore S**. Patient satisfaction with hemophilia treatment centers: difference between milds and severes from the 2nd national US HTC patient satisfaction survey. Poster. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020.
 27. **Lattimore SU**, Hofstetter MT. Patient and family engagement during treatment change to emicizumab at a hemophilia treatment center. Poster. American Society of Hematology Annual Meeting. San Diego, CA. December 2019.
 28. Pipe S, Giernasz A, Castaman G, Key NS, **Lattimore SU**, Leebeek FWG, Miesbach W, Recht M, Gomez E, Long A, Gut R, von Drygalski A. One-year data from a phase 2b trial of AMT-061 (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B. Oral presentation. American Society of Hematology Meeting. San Diego, CA. December 2019.
 29. Sidonio RF, Cheng D, Guelcher C, Journeycake JM, **Lattimore SU**, Taekmoto C, Tarantino MD, Watson C, Neufeld EJ, Fedor C. Lack of inhibitor development in the American Thrombosis and Hemostasis Network (ATHN)-2 factor switching study: preliminary report of primary outcome. Poster. American Society of Hematology Meeting, San Diego, CA. December 2019.
 30. Long A, Von Drygalski A, Giermasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Gomez E, Gut R, Pipe SW. Interim results from a phase 2b trial of AMT-061 (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia b. Oral presentation. World Hemophilia Foundation Global Forum. Montreal, Quebec. November 2019.

31. Pipe SW, Giermasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Von Drygalski A. AMT-061 (AAV5-Padua hFIX variant) an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia b: Follow-up up to 9 months in a phase 2b trial. Poster. National Hemophilia Foundation Bleeding Disorders Conference. Anaheim, CA. October 2019.
32. Baker J, Shearer R, Ashton M, **Lattimore S**. Patient satisfaction with US hemophilia treatment centers: teen transition into adult care. Poster. National Hemophilia Foundation Bleeding Disorders Conference. Anaheim, CA. October 2019.
33. **Lattimore S**, Shearer R, Ashton M, Baker J, Riske B. Patients report high satisfaction with US hemophilia treatment centers: national trends 2014 and 2017. Poster. National Hemophilia Foundation Bleeding Disorders Conference. Anaheim, CA. October 2019.
34. Olson D, Durben N, **Lattimore S**, Glenzer M, O'Connell M. The effect of bleeding disorder characteristics on patient-perceived challenges and management strategies. Oral presentation. National Hemophilia Foundation Bleeding Disorders Conference. Anaheim, CA. October 2019.
35. Von Drygalski A, Giernasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Pipe SW. A single infusion of AMT-061 is safe and effective in adults with hemophilia b: Interim results from dose-confirmation phase 2b trial. Poster. Hemostasis and Thrombosis Research Society Scientific Symposium. New Orleans, LA. May 2019.
36. **Lattimore SU**, Riske B, Ashton M, Shearer R, Baker J. Patient satisfaction with US hemophilia treatment centers: national trends 2014 and 2017. Poster. Hemostasis and Thrombosis Research Society Scientific Symposium. New Orleans, LA. May 2019.
37. **Lattimore SU**, Castaman G, Key NS, Leebeek F, Miesbach W, Recht M, Long A, Gut R, Giermasz A, Pipe S. HOPE-B: Study design of a phase III trial of an investigational gene therapy AMT-061 in adults with severe or moderately severe hemophilia B. Poster. Hemostasis and Thrombosis Research Society Scientific Symposium. New Orleans, LA. May 2019.
38. Goldscheitter G, **Lattimore S**, Taylor JA. Hemophilia associated bone pathology impacts quality of life. Oral presentation. European Hematology Association Conference. Amsterdam, the Netherlands. June 2019.
39. Goldscheitter G, **Lattimore S**, Taylor JA. Decreased skeletal health negatively impacts quality of life for people with hemophilia. Oral presentation. American Society of Hematology Meeting. Chicago, IL. December 2018.
40. O'Connell M, Oleson D, Durben N, Recht M, **Lattimore S**. The patient perspective of challenges and coping strategies in the management of bleeding disorders. Poster and Oral presentation. National Hemophilia Foundation Bleeding Disorders Conference. Orlando, FL. October 2018.
41. Cox A, Duffy Z, Recht M, **Lattimore S**. The cost of implementing a quality improvement pilot program at The Hemophilia Center at OHSU. Poster. Thrombosis and Haemostasis Societies of North America. San Diego, CA. March 2018.
42. Konkle B, Recht M, Moore M, **Lattimore S**, Schwartz E, Ito D, Epstein J, Leony Lasso I, Richardson S. SPACE (Study of prophylaxis activity and effectiveness): An interim descriptive analysis of patient

activity levels and participation. Poster. National Hemophilia Foundation Bleeding Disorders Conference. Chicago, IL. August 2017.

43. Stang E, Cox A, Boehnlein C, Recht M, **Lattimore S**. Perceptions of vulnerability, protective behaviors and reported stress in mothers of sons with hemophilia. Oral presentation. National Hemophilia Foundation Bleeding Disorders Conference. Chicago, IL. August 2017.
44. **Lattimore S**, Chapman C, Fay S, Goldstein J, Schwartz E. Patient and clinician experience using goal attainment scaling for hemophilia (GAS-hem), an innovative patient-centered outcome measure. Oral presentation. National Hemophilia Foundation Bleeding Disorders Conference. Chicago, IL. August 2017.
45. **Lattimore S**, Peters T, Tripkovic N, Ungar D. Adherence influences annualized bleeding rate during prophylaxis: results from the guardian 1 trial. Poster. National Hemophilia Foundation. Dallas, TX. August 2015.

Invited Lectures, Conference Presentations or Professorships:

International and National

1. **Lattimore S**, Shabtaie K. Fourth national patient satisfaction survey (PSS 4) technical assistance webinar for regions and hemophilia treatment centers. January 2024, Virtual.
2. **Lattimore S**. Use of program Income: the Ins and outs. Hemophilia Alliance Fall Meeting 2023. October 2023. San Antonio, TX.
3. **Lattimore S**, Shabtaie K. What patients are saying about hemophilia treatment center care, teams and services: Third national patient satisfaction survey. CDC Public Health Webinar on Blood Disorders. December 2022, Virtual.
4. **Lattimore S**. Patient interest in gene therapy for hemophilia: a regional snapshot. Plenary speaker: Hemophilia Alliance Fall Meeting 2022. September 2022. Salt Lake City, UT.
5. **Lattimore S**, Siranna V. Patient satisfaction with US hemophilia treatment centers: third national survey. Plenary speaker: National Hemophilia Foundation Monthly Update Series, November 2021, Virtual
6. **Lattimore S**, Lillicrap D, Leavitt A, Koulianos K. Gene therapy and hemophilia care updates. Symposium panel: American Society of Hematology Symposium, December 2021, Virtual
7. **Lattimore S**, Bisson E. Gene therapy and hemophilia: what every nurse should know. Gene and Innovative Therapies Education Series: National Hemophilia Foundation, December 2020, Virtual
8. **Lattimore S**, How hemophilia treatment centers work: grants, regulations and regions. Invited speaker: Hemophilia Alliance Annual Meeting, September 2020, Virtual.
9. **Lattimore S**. Patient and clinician experience using goal attainment scaling (GAS-Hem), an innovative patient-centered outcome measure. Plenary presenter: American Thrombosis and Hemostasis Network Data Summit, October 2019, Chicago IL
10. **Lattimore S**. The Hemophilia treatment center network. Plenary presenter: American Thrombosis and Hemostasis Network Data Summit, Oct 2019, Chicago, IL
11. **Lattimore S**. The role of the US regional hemophilia network. Plenary speaker: Hemophilia Alliance Annual Meeting, Sep 2019, Portland, OR

12. **Lattimore S.** Entering SPACE: patient activity levels and participation in hemophilia A. Plenary speaker: National Hemophilia Foundation Annual Meeting, Aug 2017, Chicago, IL
13. **Unipan S.** The impact of establishing a stroke center at a community hospital on the use of thrombolytic therapy: the NINDS-Suburban Hospital Stroke Center experience. Plenary speaker: American Heart Association International Stroke Conference, Aug 2000, Fort Lauderdale, FL

Regional and Local

1. **Lattimore S.** Future forward: where is care headed for people with bleeding disorders? Plenary speaker: Hemophilia Foundation of Oregon Annual Meeting, Sep 2019, Portland, OR
2. **Lattimore S.** What's research got to do with it? Hemophilia Foundation of Oregon Women's Conference, Nov 2017, Vancouver, WA.
3. **Lattimore S.** Goal setting and motivational interviewing in patient care. Invited speaker: OHSU Pediatric Hematology/Oncology Grand Rounds, 2017, Portland, OR.

V. SERVICE

Membership in Professional Societies:

Foundation for Women and Girls with Blood Disorders, 2021-ongoing
 Hemophilia and Thrombosis Research Society, 2017-ongoing
 Society of Clinical Research Associates, 2006-2018

Committees:

National

2021-present U. S. Food & Drug Administration – Blood Products Advisory Committee Member
 2021-present Science Committee – Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention
 2021-present Network Council Co-Chair – United States Hemophilia Treatment Center Network
 2018-present Hemophilia Alliance Federal Hill Days Advocate
 2016-present US Hemophilia Treatment Center Network Patient Satisfaction Survey Steering Committee
 2015-present Partners PRN: Bleeding Disorders Education Advisory Board Member
 2021-2022 National Hemophilia Foundation State of Science Bleeding Disorders Research Working Group: Health Services Research, Diversity/Equity/Inclusion Research, Implementation Science
 2019-2022 International Society on Thrombosis and Haemostasis - Lead – Train-the-Trainer Education Initiative in Hemophilia A
 2017-2020 National Hemophilia Program Coordinating Center, Quality Improvement Committee
 2018-2019 National Institutes of Health, State of the Science FVIII Inhibitor Development Working Group Member
 2017-2020 National Hemophilia Program Coordinating Center, Steering Committee, Co-Chair
 1999-2000 Nation's Capital Area Stroke Council Member, American Heart Association
 1999-2001 National Stroke Task Force, American Heart Association

Regional/Local

2022-present Ida B. Wells Working Group: Mitigate barriers to care access and quality with families

participating in OHSU NICH program
2021-present Hemophilia Center at OHSU Diversity, Equity and Inclusion Journal Club – Lead
2018-present Hemophilia Foundation of Oregon – Advocacy Ambassador
2018-2020 Childhood Cancer Study Advisory Board, OCHIN & OHSU
1997-1999 Philadelphia Stroke Council, Co-Chair

Community Service:

2021-2022 COVID-19 Volunteer Vaccinator, OHSU Vaccine Equity Committee
2015-present Coach, Oregon Youth Soccer Association (High School Co-Ed)
2014-present Health Hut Medical Provider, Camp Tapawingo Bleeding Disorders Camp
2018-2021 Friends of Cleveland Band Board Member
2015-2017 Sellwood Middle School Foundation Board Member
2012-2015 Llewellyn Elementary Foundation Board Member

AWARDS AND HONORS:

2004 Outstanding Publication “Nurses’ Week,” Vanderbilt University
1995 Nurse of the Year Award, Department of Neurology, University of Pennsylvania Medical Center
1994 Ardis Voeglin Award Clinical Excellence
1994 Sandy Lai Memorial Award, Excellence in Emergency Nursing